GL0034 is named as a drug or biological intervention in 2 clinical trials in our USA and India trial registers, 2 of which are recruiting. The lead sponsor is Sun Pharmaceutical Industries Limited. Registered phases: Phase 1 and Phase 2. Conditions studied include Type II Diabetes Mellitus.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07282743 | Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus (ClinicalTrials.gov ↗) Type II Diabetes Mellitus |
Phase 2 | Recruiting |
| NCT07385547 | Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency Type II Diabetes Mellitus |
Phase 1 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Type II Diabetes Mellitus | 2 |
| Lead sponsor | Trials |
|---|---|
| Sun Pharmaceutical Industries Limited | 2 |
| Register | GL0034 trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in India | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how GL0034 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists GL0034 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.